Jesus Mantas Net Worth

The estimated Net Worth of Jesus B Mantas is at least $919 Thousand dollars as of 9 February 2021. Mr. Mantas owns over 898 units of Biogen Inc stock worth over $585,922 and over the last 5 years he sold BIIB stock worth over $0. In addition, he makes $333,286 as Independent Director at Biogen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Mantas BIIB stock SEC Form 4 insiders trading

Jesus has made over 1 trades of the Biogen Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 898 units of BIIB stock worth $239,766 on 9 February 2021.

The largest trade he's ever made was buying 898 units of Biogen Inc stock on 9 February 2021 worth over $239,766. On average, Jesus trades about 128 units every 0 days since 2019. As of 9 February 2021 he still owns at least 2,943 units of Biogen Inc stock.

You can see the complete history of Mr. Mantas stock trades at the bottom of the page.

Jesus Mantas biography

Jesus B. Mantas serves as Independent Director of the Company. Mr. Mantas is the Managing Partner and General Manager leading worldwide strategy, offerings, digital platforms, innovation and thought leadership for IBM Global Business Services, the $17 billion unit of IBM that helps global leading enterprises design, transform and operate their businesses with digital and cloud technologies. He also serves on the board of IBM Services, the world largest technology services provider, and co-chairs the IBM Hispanic diversity council. Prior to his current role, he led globally multiple units in IBM, including Cognitive Process Transformation, Business Consulting and Global Process Services. From 2010 to 2014 Mr. Mantas lived in Brazil and led IBM Global Business Services in Latin America. From 2006 through 2010 he was Vice President of IBM Enterprise Sector in North America. Prior to joining IBM, Mr. Mantas was a partner in the High Technology practice of PricewaterhouseCoopers Consulting and an officer in the Air Force of Spain. Mr. Mantas serves in the World Economic Forum Global Artificial Intelligence Council and has been recognized as Top 25 Global Consulting Leader, Top 100 Hispanic IT Executive and Great Minds in STEM. He has degrees in telecommunications, software engineering and business administration from the Polytechnic University of Madrid and has served as professor at the Paul Merage School of Business, University of California Irvine.

What is the salary of Jesus Mantas?

As the Independent Director of Biogen Inc, the total compensation of Jesus Mantas at Biogen Inc is $333,286. There are 18 executives at Biogen Inc getting paid more, with Michel Vounatsos having the highest compensation of $18,159,900.

How old is Jesus Mantas?

Jesus Mantas is 51, he's been the Independent Director of Biogen Inc since 2019. There are 21 older and 2 younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.

What's Jesus Mantas's mailing address?

Jesus's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.

Insiders trading at Biogen Inc

Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.

What does Biogen Inc do?

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Complete history of Mr. Mantas stock trades at Biogen Inc

Biogen Inc executives and stock owners

Biogen Inc executives and other stock owners filed with the SEC include:

• Michel Vounatsos,
  Chief Executive Officer, Director
• Susan Alexander,
  Executive Vice President, Chief Legal Officer and Secretary
• Alfred Sandrock,
  Executive Vice President, Research and Development, Chief Medical Officer
• Chirfi Guindo,
  Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
• Michel Vounatsos,
  CEO & Director
• Susan H. Alexander Esq.,
  Exec. VP, Chief Legal Officer & Sec.
• Susan H. Alexander,
  Exec. VP, Chief Legal Officer & Sec.
• Michael R. McDonnell,
  Exec. VP & CFO
• Chirfi Guindo,
  Exec. VP of Global Product Strategy & Commercialization
• Stelios Papadopoulos,
  Independent Chairman of the Board
• Robert Pangia,
  Independent Director
• Brian Posner,
  Independent Director
• Alexander Denner,
  Independent Director
• Nancy Leaming,
  Independent Director
• Caroline Dorsa,
  Independent Director
• Stephen Sherwin,
  Independent Director
• Eric Rowinsky,
  Independent Director
• Richard Mulligan,
  Independent Director
• Jesus Mantas,
  Independent Director
• William Hawkins,
  Independent Director
• Robin Kramer,
  Chief Accounting Officer, Vice President
• Daniel Karp,
  Executive Vice President, Corporate Development
• Alphonse Galdes,
  Executive Vice President, Pharmaceutical Operations and Technology
• Ginger Gregory,
  Chief Human Resource Officer, Executive Vice President
• Michael McDonnell,
  Chief Financial Officer, Executive Vice President
• Dr. Sanjay Jariwala,
  Sr. VP of Worldwide Medical
• Nicole Murphy,
  Head of Pharmaceutical Operations & Technology
• Dr. Anabella Villalobos Ph.D.,
  Sr. VP of Biotherapeutic & Medicinal Sciences
• Dr. Alphonse Galdes,
  Exec. VP of Pharmaceutical Operations & Technology
• Dr. Ginger Gregory,
  Exec. VP & Chief HR Officer
• Natacha Gassenbach,
  Chief Communication Officer & Head of Corp. Affairs
• Michael Hencke,
  Director of Investor Relations
• Mark J. Hernon,
  Sr. VP & Chief Information Officer
• Robin C. Kramer,
  Sr. VP & Chief Accounting Officer
• George A Scangos,
  Chief Executive Officer
• Adriana Karaboutis,
  EVP, Tech. and Bus. Solutions
• Michael D Ehlers,
  EVP, Research and Development
• Gregory F Covino,
  VP, Chief Accounting Officer
• Lynn Schenk,
  Director
• Paul Mc Kenzie,
  EVP Pharmaceutical Oper & Tech
• Paul J Clancy,
  CFO
• Kenneth Di Pietro,
  EVP Human Resources
• Adam Koppel,
  SVP, Chief Strategy Officer
• Susan Langer,
  Director
• Jean Paul Kress,
  EVP Pres Int'l & Global Hd GTO
• Priya Singhal,
  Head of Development
• Jeffrey D Capello,
  EVP & Chief Financial Officer
• Monish D Patolawala,
  Director
• Phillip A Sharp,
  Director
• Steven H Holtzman,
  EVP Corp Devel and Strategy
• John Cox,
  EVP Pharmaceutical Oper & Tech
• Spyridon Artavanis Tsakonas,
  SVP, Chief Scientific Officer
• William Young,
  Director
• Raymond Pawlicki,
  SVP, Chief Information Officer
• Stuart A Kingsley,
  EVP, Global Comm. Operations
• Douglas E Williams,
  EVP Research & Development
• Craig Eric Schneier,
  EVP, Human Resources
• Robert E. Gagnon,
  Chief Acct Officer VP & Contr
• Francesco Granata,
  EVP Global Commercial Operatio
• James C Mullen,
  CEO and President
• Michael F Mac Lean,
  SVP, Chief Accounting Officer
• Bruce Ross,
  Director
• Robert A Hamm,
  SVP, Immunology Business Unit
• Cecil B Pickett,
  President, R & D
• Marijn E Dekkers,
  Director
• Lawrence C Best,
  Director
• Faheem Hasnain,
  SVP, Oncology SBU
• Hans Peter Hasler,
  SVP, International
• Mark C Wiggins,
  EVP - Business Development
• Michael Lytton,
  EVP Corporate & Business Devel
• Alan Glassberg,
  Director
• John Michael Dunn,
  EVP - New Ventures
• Michael Gilman,
  EVP - Research
• Thomas J Bucknum,
  EVP. General Counsel, Sec.
• Nabil Hanna,
  EVP, Research
• William H Rastetter,
  Executive Chairman
• William R Rohn,
  Exec VP & COO
• Sylvie L Gregoire,
  EVP, Bus. Dev & Program Mgmt.
• Burt A Adelman,
  EVP, Development
• Alan Belzer,
  Director
• Michael Kowolenko,
  SVP, Pharm Ops & Technology
• Peter N Kellogg,
  Executive Vice President, CFO
• Mary L Good,
  Director
• Thomas F Keller,
  Director
• Connie Matsui,
  Sr V P, Planning& Resource Dev
• Christopher Viehbacher,
  President and CEO
• Maria C Freire,
  Director
• William D /Ca/ Jones,
  Director
• Nicole Murphy,
  Head of Pharm Ops and Tech
• Rachid Izzar,
  Head of Global Product Strat.
• Adam Keeney,
  Head of Corporate Development
• Jane Grogan,
  Head of Research